Biotech Values

[genisi]

VRTX- " Piper Jaffray analyst Rachel McMinn wrote in a research note. "We view an SVR rate in the 40 percent to 50 percent range as more probable."

That's a lot lower than IDIX's board predictions:
http://www.investorshub.com/boards/read_msg.asp?message_id=15613926